Session » RA – Treatment Poster I

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0506

24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report

10:30AM-12:30PM: Abstract Number: 0536

A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease

10:30AM-12:30PM: Abstract Number: 0532

An Immune-molecular Signature Specifically Modulated by JAK Inhibitors Ex Vivo May Serve as a Predictor of Therapy Response In Vivo to These Drugs

10:30AM-12:30PM: Abstract Number: 0500

An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years

10:30AM-12:30PM: Abstract Number: 0510

Applying Machine Learning Tools for Personalized Healthcare: Predicting Responses to Biologics in Rheumatoid Patients Through Comorbidity and Blood Test Analysis

10:30AM-12:30PM: Abstract Number: 0525

Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial

10:30AM-12:30PM: Abstract Number: 0517

Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry

10:30AM-12:30PM: Abstract Number: 0512

Co-stimulatory Blockade Causes Targeted Quantitative and Clonotypic Contractions in Extrafollicular B-cell Subsets in Seropositive RA Patients

10:30AM-12:30PM: Abstract Number: 0519

Comparable Malignancy Risk of Janus Kinase Inhibitors with Conventional Synthetic and Biologic DMARDs in Asian Patients with Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers

10:30AM-12:30PM: Abstract Number: 0526

Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study

10:30AM-12:30PM: Abstract Number: 0528

Consequences of Switching Originator Biological Therapies to Its Biosimilars in Patients with Immune-mediated Diseases in a Mexican Cohort

10:30AM-12:30PM: Abstract Number: 0531

Costs and Clinical Outcomes of the Rheumatoid Arthritis Medication Tapering Cohort

10:30AM-12:30PM: Abstract Number: 0529

Discontinuation of Targeted Disease-Modifying Antirheumatic Agents in Older Patients with Rheumatoid Arthritis: Retrospective Analysis of Medicare Data

10:30AM-12:30PM: Abstract Number: 0520

Disease Duration Differentially Affects the Clinical Efficacy of Biologics and JAK Inhibitors in Rheumatoid Arthritis: The ANSWER Cohort Study

10:30AM-12:30PM: Abstract Number: 0523

Distinct Peripheral Blood Immune Cell Sub-population Signatures at Baseline of Tofacitinib or Adalimumab Initiation Are Associated to Clinical Responses at 6 Months

10:30AM-12:30PM: Abstract Number: 0511

Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial

10:30AM-12:30PM: Abstract Number: 0513

Effects of Cumulative Rituximab Exposure in Patients with Rheumatoid Arthritis: Results from Cohort at a Tertiary Academic Health Care Setting

10:30AM-12:30PM: Abstract Number: 0514

Efficacy, Safety and Mechanism of Butyrate in the Treatment of Rheumatoid Arthritis (RA)

10:30AM-12:30PM: Abstract Number: 0524

Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers

10:30AM-12:30PM: Abstract Number: 0537

Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk

10:30AM-12:30PM: Abstract Number: 0538

Factors Associated with Upadacitinib Persistence and Risk Minimization Measures in Patients with Rheumatic Diseases in a Real-world Setting. UPAreal Study

10:30AM-12:30PM: Abstract Number: 0522

Hematological Impact Assessment of Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis Treatment

10:30AM-12:30PM: Abstract Number: 0501

How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the “JAK-pot” Study)

10:30AM-12:30PM: Abstract Number: 0504

Janus Kinase Inhibitors Persist Longer Than Biologics in Rheumatoid Arthritis: Retrospective Analysis of Real-world Outpatient Data from the German Rhadar Database

10:30AM-12:30PM: Abstract Number: 0530

Long-term Effectiveness of a Lifestyle Intervention for Rheumatoid Arthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial

10:30AM-12:30PM: Abstract Number: 0516

Management of Elederly Patients with Rheumatoid Arthritis Treated with Tocilizumab : Comparison of Patients over and Under 75 Years Old

10:30AM-12:30PM: Abstract Number: 0507

Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib

10:30AM-12:30PM: Abstract Number: 0535

Oral Glucocorticoid Premedication Is at Least as Effective as Intravenous Glucocorticoid Premedication for Prevention of Infusion-related Reactions to Rituximab in Rheumatoid Arthritis Patients

10:30AM-12:30PM: Abstract Number: 0534

Patient Reported Outcomes and Disease Activity from a Phase 1 Double-Blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0508

Real-World Evidence for GP2015 in Patients with Rheumatoid Arthritis: Safety Outcomes from German Observational Data

10:30AM-12:30PM: Abstract Number: 0527

Risk Factors for Leukopenia in Asian Patients with Rheumatoid Arthritis Undergoing Tocilizumab

10:30AM-12:30PM: Abstract Number: 0515

Scavenging Isolevuglandins with 2-HOBA Decreases In Vitro Neutrophil Extracellular Traps in Cells from Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0502

Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study

10:30AM-12:30PM: Abstract Number: 0518

Sustained Patient Meaningful Outcomes of Pain and Fatigue Relief and Improved Physical Functioning with Filgotinib in Rheumatoid Arthritis: A Post Hoc Analysis

10:30AM-12:30PM: Abstract Number: 0521

Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0509

Trends in Initiation of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially-Insured US Adults, 2001-2021

10:30AM-12:30PM: Abstract Number: 0503

Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations

10:30AM-12:30PM: Abstract Number: 0505

UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi

10:30AM-12:30PM: Abstract Number: 0533

Using Adalimumab Serum Concentration to Choose a Subsequent DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (ADDORA-switch): Results of a Blinded Randomized Test Treatment Trial

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].